Listing & Compliance Notices

Liminatus Pharma, Inc. received a nasdaq noncompliance notice notice regarding late filing (rules 5250(c)(1)).

“May 29, 2025, Liminatus Pharma, Inc. (the “Company”) received a notice from the Nasdaq Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC indicating that the Company was no longer in compliance with Nasdaq Listing Rule 5250(c)(1) (the “Listing Rule”) due to the delay in filing its Quarterly Report on Form 10-Q for the period ended March 31, 2025 (the “Form 10-Q”). On June 2, 2025, the Company filed the Form 10-Q with the U.S. Securities and Exchange Commission. On June 3, 2025, the Company received a letter from the Staff stating that the Company had regained compli”

SMITH MIDLAND CORP received a nasdaq noncompliance notice notice regarding late filing (rules 5250(c)(1)).

“May 29, 2025, Smith-Midland Corporation (the “Company”), received a letter from Nasdaq indicating that the Company has regained compliance as it relates to its Annual Report on Form 10-K (“10-K”) for the year ended December 31, 2024. The Company’s 10-K was filed on May 27, 2025. On May 29, 2025, the Company received a letter from Nasdaq, indicating it was not in compliance with Nasdaq listing rule 5250(c)(1), which requires the timely filing of all required periodic financial reports with the Securities and Exchange Commission. The required filing in question is the Company’s Quarterly Report”

SMITH MIDLAND CORP received a nasdaq compliance regained notice regarding late filing (rules 5250(c)(1)).

“May 29, 2025, Smith-Midland Corporation (the “Company”), received a letter from Nasdaq indicating that the Company has regained compliance as it relates to its Annual Report on Form 10-K (“10-K”) for the year ended December 31, 2024. The Company’s 10-K was filed on May 27, 2025. On May 29, 2025, the Company received a letter from Nasdaq, indicating it was not in compliance with Nasdaq listing rule 5250(c)(1), which requires the timely filing of all required periodic financial reports with the Securities and Exchange Commission. The required filing in question is the Company’s Quarterly Report”

IRONWOOD PHARMACEUTICALS INC received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).

“the last 30 consecutive business days, the bid price for the Company’s Class A common stock, par value $0.001 per share (the “Common Stock”) had closed below the $1.00 per share minimum bid price requirement for continued inclusion on the Nasdaq Global Select Market pursuant to Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”). The deficiency letter has no immediate effect on the listing of the Company’s securities on Nasdaq. In accordance with Nasdaq Listing Rule 5810(c)(3)(A) (the “Compliance Period Rule”), the Company has been provided a period of 180 calendar days, or u”

Silexion Therapeutics Corp received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A), 5450(b)(2)(C), 5810(c)(3)(C)).

“Listing Rules 5450(b)(2)(A) and 5450(b)(2)(C), which require a company such as ours whose securities are listed on the Nasdaq Global Market under the “Market Value Standard” to maintain a minimum Market Value of Listed Securities (an “ MVLS ”) of $50,000,000 and a minimum Market Value of Publicly Held Shares (an “ MVPHS ”) of $15,000,000 for continued listing on the Nasdaq Global Market.”

BROADWAY FINANCIAL CORP \DE\ received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

“May 28, 2025, Broadway Financial Corporation (the “Company”) received written notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is not in compliance with the periodic financial reporting requirements set forth in Nasdaq Listing Rule 5250(c)(1) (“Rule 5250(c)(1)”) for continued listing on The Nasdaq Capital Market because its Quarterly Report on Form 10-Q for the quarter ended March 31, 2025 (the “Form 10-Q”) was not filed within the time period prescribed by the Securities and Exchange Commission rules. The Notice has no immediate effect on the l”

Sonnet BioTherapeutics Holdings, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).

“May 30, 2025, Sonnet BioTherapeutics Holdings, Inc. (the “Company”) received notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that it is not in compliance with the minimum stockholders’ equity requirement for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(1) requires companies listed on The Nasdaq Capital Market to maintain stockholders’ equity of at least $2,500,000 (the “Stockholders’ Equity Requirement”). In the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, the Company reported stockholders’ e”

BATTALION OIL CORP received a nyse_american noncompliance notice notice regarding stockholders equity (rules 1003(a)(i), 1003(a)(ii)).

“May 30, 2025, Battalion Oil Corporation (the “ Company ”) received written notice (the “ Notice ”) on behalf of the NYSE American LLC (the “ NYSE American ”) indicating that the Company is no longer in compliance with NYSE American’s continued listing standards. Specifically, the letter states that the Company is not in compliance with the continued listing standards set forth in Sections 1003(a)(i) and 1003(a)(ii) of the NYSE American Company Guide (the “ Company Guide ”). Section 1003(a)(i) requires a listed company to have stockholders’ equity of $2 million or more if the listed company has”

SYNTEC OPTICS HOLDINGS, INC. received a nasdaq deficiency notice notice regarding late filing (rules 5250(c)(1)).

“May 28, 2025, Syntec Optics Holdings, Inc. (the “Company”) received a delinquency notification letter (the “Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that since it has not yet filed its Form 10-Q for the period ended March 31, 2025, and because the Company remains delinquent in filing its Form 10-K for the period ended December 31, 2024, the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires listed companies to timely file all periodic financial reports with the U.S. Securities and Exchange”

Israel Acquisitions Corp received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A)).

“May 28, 2025, Israel Acquisitions Corp (the “Company”) received a deficiency letter (the “MVLS Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that, based on the market value of listed securities for the previous 30 consecutive business days, the listing of the Company’s securities was not in compliance with Nasdaq Listing Rule 5450(b)(2)(A) to maintain a minimum market value of listed securities of at least $50 million (the “MVLS Requirement”). In accordance with Nasdaq rules, the Company has a period of 180 calendar days (or unt”

RenX Enterprises Corp. received a nasdaq compliance regained notice regarding stockholders equity (rules 5550(b)(1)).

“February 14, 2025, Safe and Green Development Corporation (the “Company”) received a letter from The Nasdaq Stock Market (“Nasdaq”) stating that based on the Company’s Form 8-K, as filed with the Securities and Exchange”

Aspira Women's Health Inc. received a nasdaq deficiency notice notice regarding shareholders (rules 5635(c)).

“February 11, 2025, the Company received written notice (the “Notice”) from the Nasdaq Stock Market, LLC (“Nasdaq”) that based on the closing bid price per share immediately preceding entering into a binding agreement to”

Global Star Acquisition Inc. received a nasdaq delisting notice notice.

“January 31, 2025, the Company received a delist determination letter from Nasdaq advising the Company that Nasdaq had determined that the Company did not meet the terms of the extension. On February 7, 2025, the Company”

Agriculture & Natural Solutions Acquisition Corp received a nasdaq deficiency notice notice regarding other (rules 5620(a), 5810(c)(2)(G)).

“February 11, 2025, Agriculture & Natural Solutions Acquisition Corporation (the "Company") received a notification letter from the Listing Qualifications Staff (the "Staff") of The NASDAQ Stock Market LLC ("Nasdaq") indi”

DevvStream Corp. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“February 12, 2025, DevvStream Corp. (the “Company”) received notice (the “Notice”) from the Listing Qualifications staff of The Nasdaq Stock Market LLC (“Nasdaq”) that, because the closing bid price for the Company’s co”

Bolt Projects Holdings, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(C)).

“February 10, 2025, Bolt Projects Holdings, Inc. (the “Company”) received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecuti”

Bolt Projects Holdings, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(A)).

“February 10, 2025, Bolt Projects Holdings, Inc. (the “Company”) received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 consecuti”

byNordic Acquisition Corp received a nasdaq delisting notice notice regarding other (rules IM-5101-2).

“February 11, 2025, byNordic Acquisition Corporation, a Delaware corporation (the “ Company ”, “ BYNO ”), received a letter from the Listing Qualifications Department of The Nasdaq Stock Market (“ Nasdaq ”) stating that t”

Iterum Therapeutics plc received a nasdaq deficiency notice notice regarding audit committee (rules 5605(c)(2)(A)).

“February 14, 2025, Iterum Therapeutics plc (the “Company”), notified the Nasdaq Stock Market LLC (“Nasdaq”) that the Company will not be in compliance with the audit committee requirement under Nasdaq Listing Rule 5605(c”

Dare Bioscience, Inc. received a nasdaq delisting notice notice regarding market value (rules 5550(b)(2)).

“February 13, 2025, Nasdaq’s Listing Qualifications Department (the “Staff”) notified the Company that because the Company did not timely regain compliance with the Minimum MVLS Rule by February 10, 2025, the Company’s co”

Sotherly Hotels Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).

“February 11, 2025, Sotherly Hotels Inc. (the “Company”) received a deficiency letter (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”), notifying the Company that, for the last 30 consecutive business days, the”

FutureTech II Acquisition Corp. received a nasdaq compliance regained notice.

“February 12, 2025, FutureTech II Acquisition Corp (the “Company”) received a letter (the “Determination Letter”) from The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company had regained compliance with the listi”

Zoomcar Holdings, Inc. received a nasdaq extension granted notice regarding stockholders equity (rules 5550(b)(1)).

“February 10, 2025, the Company received a letter from the Panel (the “ Panel Decision Letter ”) stating that, based on the information presented, the Panel has determined to grant the Company’s request for continued list”

Zoomcar Holdings, Inc. received a nasdaq deficiency notice notice regarding market value (rules 5450(b)(2)(C)).

“January 23, 2025, the Company received a further notice from the Staff, notifying the Company that its failure to maintain compliance with the market value of publicly held shares requirement for continued listing on The”

Royalty Management Holding Corp received a nasdaq extension granted notice regarding shareholders (rules 5620(a)).

“February 12, 2025, Nasdaq provided the Company with written notification that its staff has determined to grant the Company an extension until June 30, 2025 to regain compliance with Listing Rule 5620(a) pursuant to the”

Royalty Management Holding Corp received a nasdaq deficiency notice notice regarding shareholders (rules 5620(a)).

“January 29, 2025, Royalty Management Holding Corporation (or the “Company”) disclosed that the Company had received a letter from Nasdaq Regulation (“Nasdaq”) indicating that the Company has not yet held an annual meetin”

Banzai International, Inc. received a nasdaq compliance regained notice regarding other (rules 5550(a)(2), 5550(a)(5), 5550(b)(1)).

“February 12, 2025, the Company received a letter from the Nasdaq Stock Market LLC, Office of the General Counsel that Nasdaq’s Listing Qualifications staff confirmed that the Company has demonstrated compliance with all”

Ovid Therapeutics Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).

“February 10, 2025, Ovid Therapeutics Inc. (the “Company”) received a notification letter from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the average”

Clearside Biomedical, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).

“February 7, 2025, Clearside Biomedical, Inc. (the “ Company ”) received a notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“ Nasdaq ”) notifying the Company that the listing of its common”

RenX Enterprises Corp. received a nasdaq extension granted notice regarding stockholders equity (rules 5550(b)(1)).

“January 22, 2025, the Company received written notification from Nasdaq granting the Company’s request for an extension through February 24, 2025 to evidence compliance with the Rule. The terms of the extension are as fo”

MGO Global Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“February 6, 2025, MGO Global Inc., a Delaware corporation (the “ Company ”), received a written notice (the “ Notice ”) from The Nasdaq Stock Market LLC (“ Nasdaq ”) notifying the Company that it is not in compliance wit”

Alternus Clean Energy, Inc. received a nasdaq delisting notice notice regarding market value (rules 5550(b)(2), 5550(a)(2)).

“February 10, 2025, the Company received a determination letter (the “Delisting Notification”) from the Nasdaq Hearings Advisor stating that the Panel has determined to delist the Company’s common stock, par value $0.0001”

Genprex, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“February 7, 2025, Genprex, Inc. (the “Company”) received a letter from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market (“Nasdaq”) notifying the Company that, based upon the closing bid pric”

Staffing 360 Solutions, Inc. received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)(1)).

“February 11, 2025, Staffing 360 Solutions, Inc. (the “ Company ”) received a letter (the “ Decision Letter ”) from the Nasdaq Stock Market LLC, stating that as the Company was unable to comply with the terms of the Octob”

Big Digital Energy, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“February 6, 2025, Mawson Infrastructure Group Inc. (the “Company”) received written notice (the “Bid Price Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notif”

URBAN ONE, INC. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“February 11, 2025, Urban One Inc. (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 30 co”

AMERICAN REBEL HOLDINGS INC received a nasdaq compliance regained notice regarding late filing (rules 5250(c)(1)).

“February 10, 2025, the Company received a written notification from the Staff indicating that the Company had regained compliance with the periodic filing requirement under Nasdaq Listing Rules.”

Applied Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).

“February 7, 2025, Applied Therapeutics, Inc. (the “ Company ”) received written notification (the “ Notice ”) from the Nasdaq Stock Market (“ Nasdaq ”) that, because the closing bid price for the Company’s common stock h”

NSTS Bancorp, Inc. received a nasdaq deficiency notice notice regarding board independence (rules 5605(b)(1)).

“February 7, 2025, the Company received a letter from Nasdaq confirming that, due to Mr. Bond’s death, the Company has temporarily fallen out of compliance with the requirements of Rule 5605(b)(1) of the Nasdaq listing st”

Processa Pharmaceuticals, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“February 4, 2025, Processa Pharmaceuticals, Inc. (the “Company”) received a letter (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company t”

ECD Automotive Design, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

“February 5, 2025, ECD Automotive Design Inc., a Delaware corporation (the “Company”), received a notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”), stating that the Company’s common stock failed to mainta”

ALPHA MODUS HOLDINGS, INC. received a nasdaq deficiency notice notice regarding market value.

“February 5, 2025, Alpha Modus Holdings, Inc. (the “ Company ”) received a written notice (the “ Notice ”) from the Listing Qualifications Department of The Nasdaq Stock Market (“ Nasdaq ”) indicating that the Company no”

Evergreen Corp received a nasdaq deficiency notice notice regarding shareholders (rules 5450(a)(2)).

“February 3, 2025, Evergreen Corporation (the “Company”) received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company did not comply with the minimum 400 total shareholders requirement for contin”

AEON Biopharma, Inc. received a nyse_american noncompliance notice notice regarding stockholders equity (rules 1003(a)(i)).

“February 3, 2025, AEON Biopharma, Inc. (the “Company” or “AEON”) received a written notice of non-compliance (the “Notice”) from the NYSE American LLC (the “NYSE American”) stating that the Company is not in compliance w”

HCW Biologics Inc. received a nasdaq delisting notice notice regarding other (rules 5810(c)(3)(A), 5450(b)(2)).

“February 5, 2025, the Staff notified the Company that its securities were subject to delisting from Nasdaq unless the Company timely requests a hearing before the Nasdaq Hearing Panel (the “Panel”). As previously disclos”

BioAtla, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“February 6, 2025, BioAtla, Inc. (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company is not in compliance wi”

IN8BIO, INC. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).

“February 5, 2025, IN8bio, Inc. (the “Company”) received a notice (the “Extension Notice”) from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) informing the Company that Nasdaq granted the Com”

bioAffinity Technologies, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

“February 7, 2025, bioAffinity Technologies, Inc. (the “Company”) received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that for the preceding 3”

Solana Co received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2)).

“February 7, 2025, the Company received a letter from the Staff indicating the Company’s continued non-compliance with the Minimum Bid Price Requirement. The letter further informed the Company that the Company’s common s”

REGIONAL HEALTH PROPERTIES, INC received a nyse_american delisting notice notice regarding stockholders equity (rules 1003(a)(i), 1003(a)(ii)).

“February 3, 2025, Regional received a letter from the Panel (the “Letter”), that based upon the material and information presented to the Panel, discussion that occurred at the hearing and analysis of the Exchange rules”